Bimekizumab
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nonradiographic Axial Spondyloarthritis
Conditions
Nonradiographic Axial Spondyloarthritis
Trial Timeline
Apr 25, 2019 → Apr 17, 2023
NCT ID
NCT03928704About Bimekizumab
Bimekizumab is a phase 3 stage product being developed by UCB for Nonradiographic Axial Spondyloarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03928704. Target conditions include Nonradiographic Axial Spondyloarthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06888193 | Phase 1 | Recruiting |
| NCT06921850 | Phase 3 | Recruiting |
| NCT06668181 | Phase 3 | Recruiting |
| NCT06506916 | Phase 3 | Recruiting |
| NCT06336343 | Approved | Recruiting |
| NCT06011733 | Phase 3 | Completed |
| NCT05292131 | Phase 1 | Completed |
| NCT05020249 | Phase 3 | Completed |
| NCT04901195 | Phase 3 | Active |
| NCT04718896 | Phase 2 | Completed |
| NCT04436640 | Phase 3 | Active |
| NCT04242498 | Phase 3 | Completed |
| NCT04242446 | Phase 3 | Completed |
| NCT04255862 | Phase 1 | Terminated |
| NCT04009499 | Phase 3 | Active |
| NCT04109976 | Phase 3 | Completed |
| NCT03928743 | Phase 3 | Completed |
| NCT03928704 | Phase 3 | Completed |
| NCT03895385 | Phase 1 | Completed |
| NCT03896581 | Phase 3 | Completed |